Systemic inflammation in chronic obstructive pulmonary disease

European Respiratory Journal, Supplement

Volumn 22, Issue 46, 2003, Pages

  Oudijk, E J D ^a   Lammers, J W J ^a   Koenderman, L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chronic obstructive pulmonary; Disease; Systemic inflammation

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CATHEPSIN B; CD11B ANTIGEN; CD18 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CIGARETTE SMOKE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LEUKOSIALIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PROTEINASE; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SERINE PROTEINASE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE; LEUKOCYTE ACTIVATION; MUSCLE ATROPHY; PRIORITY JOURNAL; REVIEW; SPIROMETRY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; INFLAMMATION; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RESPIRATORY SYSTEM; SKELETAL MUSCLE; SMOKING; WEIGHT REDUCTION;

HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; MUSCLE, SKELETAL; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SMOKING; WEIGHT LOSS;

EID: 0242362831     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117: 1s-4s.
2. National Heart LaBI. Morbidity & Mortality: 2002 Chartbook on Cardiovascular, Lung and Blood Diseases. www.nhlbi.nih.gov/resources/docs/02_chtbk. pdf 2002. Date updated: May 2002; Date accessed: November 2002.
3. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
4. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: Suppl. 5, 1s-28s.
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77-S121.
6. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
7. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/ WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
8. Wedzicha JA. Exacerbations: etiology and pathophysiologic mechanisms. Chest 2002; 121: 136s-141s.
9. Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264-1270.
10. Patel IS, Seemungal TA, Wilks M, SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
11. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
12. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-390.
13. Rennard SI, Daughton DM. Smoking cessation. Chest 2000; 117: 360s-364s.
14. Perez-Padilla R, Regalado J, Vedal S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. Am J Respir Crit Care Med 1996; 154: 701-706,
15. Dossing M, Khan J, al-Rabiah F. Risk factors for chronic obstructive lung disease in Saudi Arabia. Respir Med 1994; 88: 519-522.
16. Behera D, Jindal SK, Malhotra HS. Ventilatory function in nonsmoking rural Indian women using different cooking fuels. Respiration 1994; 61: 89-92.
17. Amoli K. Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur Respir J 1998; 11: 659-663.
18. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983; 128: 833-838.
19. Sato E, Koyama S, Takamizawa A, et al. Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities. Am J Physiol 1999; 277: L1149-L1157.
20. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S29-S32.
21. Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S12-S16.
22. Wang H, Liu X, Umino T, et al. Cigarette smoke inhibits human bronchial epithelial cell repair processes. Am J Respir Cell Mol Biol 2001; 25: 772-779.
23. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
24. Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology 2002; 180: 121-137.
25. Gokkusu C, Ademoglu E, Tamer S, Alkan G. Oxidant-antioxidant profiles of platelet rich plasma in smokers. Addict Biol 2001; 6: 325-330.
26. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21: 669-681.
27. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357.
28. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62.
29. Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am J Respir Cell Mol Biol 2000; 22: 244-252.
30. Dhami R, Zay K, Gilks B, Porter S, Wright JL, Churg A. Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. J Mol Med 1999; 77: 377-385.
31. Janoff A, Carp H. Possible mechanisms of emphysema in smokers: cigarette smoke condensate suppresses protease inhibition in vitro. Am Rev Respir Dis 1977; 116: 65-72.
32. Janoff A, George-Nascimento C, Rosenberg S. A genetically engineered, mutant human alpha-1-proteinase inhibitor is more resistant than the normal inhibitor to oxidative inactivation by chemicals, enzymes, cells, and cigarette smoke. Am Rev Respir Dis 1986; 133: 353-356.
33. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med 2002; 166: 954-960.
34. Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 1982; 79: 2041-2045.
35. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002; 121: 151s-155s.
36. Maestrelli P, Saetta M, Mapp CE, Fabbri LM. Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: S76-S80.
37. Cosio MG, Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma Am J Respir Crit Care Med 1999; 160: S21-S25.
38. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F Filley Lecture. Chest 2000; 117: 251s-260s.
39. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160: S49-S52.
40. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002; 121: 156s-159s.
41. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152: 1666-1672.
42. Zhu YK, Liu XD, Skold CM, et al. Synergistic neutrophil elastase-cytokine interaction degrades collagen in three-dimensional culture. Am J Physiol Lung Cell Mol Physiol 2001; 281: L868-L878.
43. Turino GM. The origins of a concept: the protease-antiprotease imbalance hypothesis. Chest 2002; 122: 1058-1060.
44. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998; 78: 1077-1087.
45. Shapiro SD. Animal models for COPD. Chest 2000; 117: 223s-227s.
46. Lucey EC, Stone PJ, Breuer R, et al. Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with in vitro observations on elastolysis by these enzymes. Am Rev Respir Dis 1985; 132: 362-366.
47. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest 1988; 82: 1963-1973.
48. Lesser M, Padilla ML, Cardozo C. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am Rev Respir Dis 1992; 145: 661-668.
49. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000; 106: 1081-1093.
50. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110.
51. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
52. Churg A, Zay K, Shay S, et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol 2002; 27: 368-374.
53. Piotrowski WJ, Marczak J. Cellular sources of oxidants in the lung. Int J Occup Med Environ Health 2000; 13: 369-385.
54. Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med 1999; 160: 2086-2092.
55. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: S28-S38.
56. Tiddens H, Silverman M, Bush A. The role of inflammation in airway disease: remodeling. Am J Respir Crit Care Med 2000; 162: S7-S10.
57. Knight D. Epithelium-fibroblast interactions in response to airway inflammation. Immunol Cell Biol 2001; 79: 160-164.
58. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190: 619-626.
59. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218-1224.
60. Mengelers HJ, Maikoe T, Brinkman L, Hooibrink B, Lammers JW, Koenderman L. Immunophenotyping of eosinophils recovered from blood and BAL of allergic asthmatics. Ant J Respir Crit Care Med 1994; 149: 345-351.
61. Warringa RA, Mengelers HJ, Kuijper PH, Raaijmakers JA, Bruijnzeel PL, Koenderman L. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals. Blood 1992; 79: 1836-1841.
62. Koenderman L, Coffer PJ. Controlling allergic inflammation by signaling regulation of eosinophils. Allergy 2001; 56: 204-214.
63. Koenderman L, Kanters D, Maesen B, et al. Monitoring of neutrophil priming in whole blood by antibodies isolated from a synthetic phage antibody library. J Leukoc Biol 2000; 68: 58-64.
64. Coffer PJ, Koenderman L. Granulocyte signal transduction and priming: cause without effect? Immunol Lett 1997; 57: 27-31.
65. Koenderman L, van der BT, Schweizer RC, et al. Eosinophil priming by cytokines: from cellular signal to in vivo modulation. Eur Respir J 1996; 9: Suppl. 22, 119s-125s.
66. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002; 283: C1592-C1603.
67. Ernst M, Inglese M, Scholz GM, et al. Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response. J Exp Med R 2002; 196: 589-604.
68. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 2002; 166: 479-484.
69. Riyami BM, Tree R, Kinsella J, et al. Changes in alveolar macrophage, monocyte, and neutrophil cell profiles after smoke inhalation injury. J Clin Pathol 1990; 43: 43-45.
70. Masubuchi T, Koyama S, Sato E, et al. Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol 1998; 153: 1903-1912.
71. Bergmann S, Siekmeier R, Mix C, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol 1998; 114: 269-275.
72. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD. Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 1994; 160: 154-162.
73. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
74. Basili S, Ferroni P, Vieri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis 1999; 147: 249-252.
75. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567-572.
76. Van Tiel E, Peeters PH, Smit HA, et al. Quitting smoking may restore hematological characteristics within five years. Ann Epidemiol 2002; 12: 378-388.
77. Sunyer J, Munoz A, Peng Y, et al. Longitudinal relation between smoking and white blood cells. Am J Epidemiol 1996; 144: 734-741.
78. Freedman DS, Flanders WD, Barboriak JJ, Malarcher AM, Gates L. Cigarette smoking and leukocyte subpopulations in men. Ann Epidemiol 1996; 6: 299-306.
79. Freedman DS, Joesoef MR, Barboriak JJ, Stallone DD, Byers T. Correlates of leukocyte counts in men. Ann Epidemiol 1996; 6: 74-82.
80. Bosken CH, Hards J, Gatter K, Hogg JC. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis 1992; 145: 911-917.
81. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. The effect of cigarette smoking on the bone marrow. Am J Respir Crit Care Med 1997; 155: 1021-1026.
82. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001; 56: 432-437.
83. Gustafsson A, Asman B, Bergstrom K. Cigarette smoking as an aggravating factor in inflammatory tissue-destructive diseases. Increase in tumor necrosis factor-alpha priming of peripheral neutrophils measured as generation of oxygen radicals. Int J Clin Lab Res 2000; 30: 187-190.
84. Koethe SM, Kuhnmuench JR, Becker CG. Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody. Am J Pathol 2000; 157: 1735-1743.
85. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Chest 2000; 117: 262s.
86. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152: 1262-1267.
87. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
88. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: Suppl. 34, 50s-59s.
89. Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56: 721-726.
90. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1179-1184.
91. Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest 2002; 122: 416-420.
92. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 420-422.
93. Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000; 118: 971-975.
94. Lewis SA, Pavord ID, Stringer JR, Knox AJ, Weiss ST, Britton JR. The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults. Chest 2001; 119: 105-114.
95. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002; 132: 414-422.
96. Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2002; 4: Suppl. 2, S34-S40.
97. Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract 2001; 55: 211-216.
98. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002; 121: 127S-130S.
99. Wouters EF. Chronic obstructive pulmonary disease. 5: Systemic effects of COPD. Thorax 2002; 57: 1067-1070.
100. Coats AJ. Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. Int J Cardiol 2002; 85: 133-139.
101. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85: 89-99.
102. Baronzio G, Zambelli A, Comi D, et al. Proinflammatory and regulatory cytokine levels in AIDS cachexia. In Vivo 1999; 13: 499-502.
103. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002; 85: 51-66.
104. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002; 85: 161-171.
105. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12: 871-880.
106. Ladner KJ, Caligiuri MA, Guttridge DC. TNF regulated biphasic activation of NF-kB is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem 2003; 24278: 2294-2303.
107. Langen RC, Schols AM, Kelders MC, Van Dcr Velden JL, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol 2002; 283: C714-C721.
108. Davies D, Holgate S. Asthma: the importance of epithelial mesenchymal communication in pathogenesis. Inflammation and the airway epithelium in asthma. Int J Biochem Cell Biol 2002; 34: 1520.
109. Ulfman LH, Joosten DP, van der Linden JA, Lammers JW, Zwaginga JJ, Koenderman L. IL-8 induces a transient arrest of rolling eosinophils on human endothelial cells. J Immunol 2001; 166: 588-595.
110. Ulfman LH, Kuijper PH, van der Linden JA, Lammers JW, Zwaginga JJ, Koenderman L. Characterization of eosinophil adhesion to TNF-alpha-activated endothelium under flow conditions: alpha 4 integrins mediate initial attachment, and E-selectin mediates rolling. J Immunol 1999; 163: 343-350.
111. Pettersen CA, Adler KB. Airways inflammation and COPD: epithelial-neutrophil interactions. Chest 2002; 121: 142S-150S.
112. Liddington RC, Ginsberg MH. Integrin activation takes shape. J Cell Biol 2002; 158: 833-839.
113. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.
114. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997; 29: 491-497.
115. Schaberg T, Rau M, Oerter R, et al. Expression of adhesion molecules in peripheral pulmonary vessels from smokers and nonsmokers. Lung 1996; 174: 71-81.
116. Schaberg T, Lauer C, Lode H, Fischer J, Haller H. Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects. Association with cell-binding ability and superoxide anion production. Am Rev Respir Dis 1992; 146: 1287-1293.
117. Godessart N, Kunkel SL. Chemokines in autoimmune disease. Curr Opin Immunol 2001; 13: 670-675.
118. Ruth JH, Rottman JB, Katschke KJJ, et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001; 44: 2750-2760.
119. Katschke KJJ, Rottman JB, Ruth JH, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1022-1032.
120. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 22: 199-204,
121. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997; 99: 439-446.
122. Douglas MR, Morrison KE, Salmon M, Buckley CD. Why does inflammation persist: a dominant role for the stromal microenvironment? Exp Rev Mol Med 2002. www. expertreviews.org/02005264h.htm. Date updated: September 12 2002; Date accessed: November 2002.
123. Levine SJ, Larivee P, Logun C, Angus CW, Shelhamer JH. Corticosteroids differentially regulate secretion of IL-6, IL-8, and G-CSF by a human bronchial epithelial cell line. Am J Physiol 1993; 265: L360-L368.
124. Nocker RET, Weller FR, Out TA, de Riemer MJ, Jansen HM, van der Zee JS. Effect of fluticasone propionate on inflammatory indices in bronchoalveolar lavage fluid and on bronchial hyperresponsiveness in patients with asthma. Airway Inflammation in Asthma. Studies on Allergen Challenge and Corticosteroid Treatment; Thesis. Wageningen, The Netherlands, Ponsen&Looijen, 1998; 49-71.
125. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639.
126. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
127. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
128. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 342-344.
129. Zhang X, Moilanen E, Kankaanranta H. Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 2001; 431: 365-371.
130. Chilvers ER, Rossi AG, Murray J, Haslett C. Regulation of granulocyte apoptosis and implications for anti-inflammatory therapy. Thorax 1998; 53: 533-534.
131. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156: 4422-4428.